Endocrine Therapy
Extended adjuvant letrozole improves DFS among certain postmenopausal women with breast cancer
SAN ANTONIO — Extended adjuvant endocrine therapy with letrozole improved DFS compared with placebo among postmenopausal women with hormone receptor-positive breast cancer who completed previous adjuvant therapy with an aromatase inhibitor, according to 10-year results from the randomized NRG Oncology/NSABP B-42 trial presented at San Antonio Breast Cancer Symposium.
Addition of S-1 to adjuvant endocrine therapy increases invasive DFS in breast cancer subset
SAN ANTONIO — The addition of the oral fluoropyrimidine S-1 to adjuvant endocrine therapy significantly extended invasive disease-free survival among certain women with hormone receptor-positive, HER2-negative breast cancer, according to results of the randomized phase 3 POTENT trial presented at San Antonio Breast Cancer Symposium.
VIDEO: Assessing when to escalate, de-escalate therapy in early breast cancer
In this video, Walker Lyons, MD, breast surgery fellow with Fox Chase Cancer Center, discusses the treatment landscape in early breast cancer.